A detailed history of Alliancebernstein L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 184,211 shares of DYN stock, worth $5.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
184,211
Previous 255,365 27.86%
Holding current value
$5.52 Million
Previous $9.01 Million 26.58%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$31.94 - $47.04 $2.27 Million - $3.35 Million
-71,154 Reduced 27.86%
184,211 $6.62 Million
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $2.06 Million - $3.1 Million
87,014 Added 51.69%
255,365 $9.01 Million
Q1 2024

May 14, 2024

SELL
$13.06 - $29.18 $1.46 Million - $3.26 Million
-111,763 Reduced 39.9%
168,351 $4.78 Million
Q4 2023

Feb 14, 2024

BUY
$6.62 - $13.64 $192,827 - $397,305
29,128 Added 11.61%
280,114 $3.73 Million
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $987,615 - $1.4 Million
-114,839 Reduced 31.39%
250,986 $2.25 Million
Q2 2023

Aug 15, 2023

BUY
$8.53 - $14.28 $321,691 - $538,541
37,713 Added 11.49%
365,825 $4.12 Million
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $147,141 - $202,860
13,524 Added 4.3%
328,112 $3.78 Million
Q4 2022

Feb 14, 2023

BUY
$9.37 - $13.8 $431,610 - $635,669
46,063 Added 17.15%
314,588 $3.65 Million
Q3 2022

Nov 15, 2022

BUY
$7.2 - $15.17 $143,236 - $301,791
19,894 Added 8.0%
268,525 $3.41 Million
Q2 2022

Aug 15, 2022

BUY
$4.36 - $10.5 $284,843 - $685,975
65,331 Added 35.64%
248,631 $1.71 Million
Q1 2022

May 13, 2022

BUY
$6.52 - $12.27 $1.2 Million - $2.25 Million
183,300 New
183,300 $1.77 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.55B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.